HYBRID EVENT: You can participate in person at Germany or Virtually from your home or work.

4th Edition of Euro-Global Conference on Biotechnology and Bioengineering

September 19-21 | Hybrid Event

September 19-21, 2024 | Germany
ECBB 2022

Biyue Zhu

Biyue Zhu, Speaker at Biotechnology Conferences 2022
Massachusetts general hospital, United States
Title: Differentiating Alpha Beta 40 and Alpha Beta 42 in amyloid plaques with a small molecule fluorescence probe


Differentiating amyloid beta (Aβ) subspecies Aβ40 and Aβ42 has long been considered an impossible mission with small-molecule probes. In this report, based on recently published structures of Aβ fibrils, we designed iminocoumarin–thiazole (ICT) fluorescence probes to differentiate Aβ40 and Aβ42, among which Aβ42 has much higher neurotoxicity. We demonstrated that ICTAD-1 robustly responds to Aβ fibrils, evidenced by turn-on fluorescence intensity and red-shifting of emission peaks. Remarkably, ICTAD-1 showed different spectra towards Aβ40 and Aβ42 fibrils. In vitro results demonstrated that ICTAD-1 could be used to differentiate Aβ40/42 in solutions. Moreover, our data revealed that ICTAD-1 could be used to separate Aβ40/42 components in plaques of AD mouse brain slides. In addition, two-photon imaging suggested that ICTAD-1 was able to cross the BBB and label plaques in vivo. Interestingly, we observed that ICTAD-1 was specific toward plaques, but not cerebral amyloid angiopathy (CAA) on brain blood vessels. Given Aβ40 and Aβ42 species have significant differences of neurotoxicity, we believe that ICTAD-1 can be used as an important tool for basic studies and has the potential to provide a better diagnosis in the future.


Dr. Zhu received her Ph.D degree in pharmaceutics at Sichuan University. She works as an exchange student at massachusetts general hospital/harvard medical school during her Ph.D study. Currently, she works as a postdoc at massachusetts general hospital/harvard medical school. Her research field is related with the imaging probe, therapeutics, and drug screening platform of Alzheimer's disease.